Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Orthopedic major, Stryker Corp. (SYK - Analyst Report) has launched the Iconix all suture anchor platform with IntelliBraid technology at the American Academy of Orthopaedic Surgeons 2013 Annual Meeting. The device is used in shoulder and hip arthroscopy surgeries.

The Iconix family of anchors from Stryker's Joint Preservation business represents the next generation suture anchor technology with innovative design. Iconix has been around since the first use of all suture fixation technology in clinical cases in 1998.

Stryker acquired this pioneering all suture platform from Laurane Medical, which it took over in 2011. Since then, the company has invested in developing the technology to meet the current operating room needs and allow more flexibility to doctors.

Stryker, with a market-cap of $24.65 billion, is one of the largest medical device manufacturers operating in the global orthopedic market. The ongoing turnaround in the company’s core Reconstructive business is a major positive for Stryker.

The company’s well-diversified product portfolio, expanding foothold in emerging markets along with acquisitions are expected to drive future growth. Recently, it completed the acquisition of China-based Trauson Holdings to grow its market share in the value-oriented orthopedic segment in developing nations.

Moreover, the company remains committed in delivering incremental returns to investors, as reflected in the recent hike in dividend and sizeable share repurchase program.

However, Stryker faces several challenges, which include continued soft international sales and tough hospital capital budgets. Despite the recent stability in the domestic market, the company remains challenged by the prevailing austerity measures in Europe.

Stryker carries a Zacks Rank #3 (Hold). Companies like Abaxis ((ABAX - Analyst Report)), Edwards Lifesciences ((EW - Analyst Report)) and Hanger (HGR - Analyst Report), each carrying a Zacks Rank #2 (Buy), are expected to do well in the medical industry.
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
GENERAL FINA GFN 8.20 +5.67%
QIHOO 360 TE QIHU 91.57 +4.38%
VIPSHOP HOLD VIPS 140.01 +3.49%
INVEST TECH- ITG 19.16 +3.34%
VERTEX ENERG VTNR 7.38 +3.07%